



PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/085,972
Filing Date	February 28, 2002
First Named Inventor	K. Bechtold-Peters et al.
Art Unit	1615
Examiner Name	To be assigned
Attorney Docket Number	1/1197

Sheet 1 of 2

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ht		US- 4,533,542	08/06/1985	Buddenbaum & Robison	RECEIVED APR 15 2003 TECH CENTER 1600/2900
ht		US- 3,082,154	03/19/1963	Lionel Victor Allan	
ht		US- 4,540,602	09/10/1985	Shimesu Motoyama et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
ht		WO 92/08447	05/29/1992	Glaxo Group Limited		
ht		WO 00/57881	10/5/2000	Otsuka Pharmaceutical Co., Ltd		
ht		WO 92/09322	06/11/1992	Boehringer Ingelheim International GMBH		

Examiner  
Signature

Kishu

Date  
Considered

6/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/085,972		
		Filing Date	February 28, 2002		
		First Named Inventor	K. Bechtold-Peters et al.		
		Art Unit	1615		
		Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	1/1197

RECEIVED  
APR 15 2003  
TECH CENTER 1600/P300

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
hse		CASSIDY O ET AL: "The effect of surface modification on electrostatic charge of a particulate solid." EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 4, no. SUPPL., 1996, page S65 XP002232704 Third European Congress of Pharmaceutical Sciences; Edinburgh, Scotland, UK; September 15-17, 1996 ISSN: 0928-0987 abstract	
		NGUYEN H ET AL: "The potential of surface modification to improve wetting, dissolution and electrostatic charge of a hydrophobic drug." JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 49, no. SUPPL. 4, 1997, page 41 XP009005828 134th Meeting of the British Pharmaceutical Conference, Scarborough, England, UK; September 15-18, 1997 ISSN: 0022-3573 abstract	
		CASSIDY O E ET AL: "Surface modification and electrostatic charge of polystyrene particles." INTERNATIONAL JOURNAL OF PHARMACEUTICS, NETHERLANDS 25 May 1999, vol. 182, no. 2, 25 May 1999 (1999-05-25), pages 199-211, XP01145533 ISSN: 0378-5173 page 199-page 200, page 209, column 2, page 204, column 2, last paragraph	
		CASSIDY, O.E. AND ROWLEY, G.: "The effect of drug surface modification by adsorbed polymer on electrostatic charge" PROC. PHARM. TECH. CONF., vol. 16, no. 3 1997, pages 5-11, XP009005985 page 5, paragraph 1	
		ROWLEY G ET AL: "The development of a particle carrier technique to aid the investigation of electrostatic charging properties of micronized pharmaceutical powders." JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 47, no. 12B, 1995, page 1100 XP009005825 British Pharmaceutical Conference 1995: Science Proceedings of the 132nd Meeting; Warwick, England, UK; September 15-18, 1995 ISSN: 0022-0375, sentences 1-8	
hse		CARTER P A ET AL: "Electrostatic charge on inhaled powders." EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 6, no. SUPPL. 1, August 1998 (1998-08), page S63 XP002232941 Third European Congress of Pharmaceutical Sciences; Milan, Italy; September 11-13, 1998 ISSN: 0928-0987 page 1-3	

Examiner Signature	Kuhn	Date Considered	6/04
--------------------	------	-----------------	------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.